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Despite being relatively rare, drug-induced liver injury (DILI) is a serious condition,
both for the individual patient due to the risk of acute liver failure, and for the
drug development industry and regulatory agencies due to associations with drug
development attritions, black box warnings, and postmarketing withdrawals. A major
limitation in DILI diagnosis and prediction is the current lack of specific biomarkers.
Despite refined usage of traditional liver biomarkers in DILI, reliable disease outcome
predictions are still difficult to make. These limitations have driven the growing interest
in developing new more sensitive and specific DILI biomarkers, which can improve
early DILI prediction, diagnosis, and course of action. Several promising DILI biomarker
candidates have been discovered to date, including mechanistic-based biomarker
candidates such as glutamate dehydrogenase, high-mobility group box 1 protein and
keratin-18, which can also provide information on the injury mechanism of different
causative agents. Furthermore, microRNAs have received much attention lately as
potential non-invasive DILI biomarker candidates, in particular miR-122. Advances in
“omics” technologies offer a new approach for biomarker exploration studies. The
ability to screen a large number of molecules (e.g., metabolites, proteins, or DNA)
simultaneously enables the identification of ‘toxicity signatures,’ which may be used to
enhance preclinical safety assessments and disease diagnostics. Omics-based studies
can also provide information on the underlying mechanisms of distinct forms of DILI
that may further facilitate the identification of early diagnostic biomarkers and safer
implementation of personalized medicine. In this review, we summarize recent advances
in the area of DILI biomarker studies.
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INTRODUCTION
Drug-induced liver injury (DILI) is one of many forms of adverse drug reactions that appear in a
small proportion of patients. DILI is generally classified as intrinsic if predictable based on dose
and pharmacological properties [for example acetaminophen (APAP) overdose] or idiosyncratic
when unpredictable by the same features. The latter is believed to be a consequence of interactions
between drug properties, host factors, and environmental conditions in a susceptible individual.
Hence, no functional animal models are currently available for idiosyncratic DILI, unlike the
presence of well-established murine models for APAP hepatotoxicity. DILI can have a profound
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impact on patient health due to its potential to cause acute
liver failure, although most idiosyncratic DILI cases have a
favorable outcome with full recovery after withdrawal of the
culprit drug. DILI presents a clinical challenge as it can mimic
almost any acute or chronic hepatobiliary condition and there are
currently no specific biomarkers or diagnostic test available for
this condition. A clinical diagnosis of idiosyncratic DILI therefore
relies heavily on exclusion of alternative causes and a compatible
drug history. The lack of DILI specific biomarkers also affects the
drug development process and can result in early termination
of drug candidates with assumed idiosyncratic hepatotoxicity
potential. This can have considerable economic consequences
and can prevent a large targeted recipient group from benefitting
from a drug that may only be harmful to a small proportion
of patients. New more specific and sensitive DILI biomarkers
could enable better monitoring of patients receiving new drugs
and minimize liver injury through early detection and subsequent
cessation of dosing.
CURRENT BIOMARKERS IN DILI
Diagnosis
A biomarker is defined as a characteristic that is objectively
measured and evaluated as an indicator of normal biological
processes, pathogenic processes or pharmacologic responses to
a therapeutic intervention (Biomarkers Definitions Working
Group, 2001). While of uttermost importance in preclinical
and early-phase clinical trial efficacy and safety evaluations of
new drug compounds, biomarkers also play important roles
in clinical practice to diagnose specific diseases, determine the
state of a disease, disease prognosis and monitoring of clinical
response to an intervention. Due to the lack of specific DILI
biomarkers, DILI is monitored and diagnosed based on general
liver injury serum biomarkers, such as alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), and total bilirubin (TBL). ALT, AST, and ALP are all
intracellular enzymes, which when detected in serum can indicate
injury to hepatocytes or biliary cells. An increase in serum TBL on
the other hand reflects liver dysfunction, but while being liver-
specific it is relatively insensitive and subsequently appears later
along the disease progression. ALT, AST, and ALP are not liver-
specific and extrahepatic conditions such as myocardial damage,
skeletal muscle diseases, hyperthyroidism, and bone diseases
are associated with increased ALT, AST, or ALP. Interestingly,
evidence of ALT and ALP plasma levels being influenced by
genetic variations are also emerging (Yuan et al., 2008).
Alanine aminotransferase is thought to be more specific for
liver injury than AST, as it is present mainly as a cytosolic
protein in the liver and in low concentrations elsewhere, while
AST is present in both cytosolic and mitochondrial forms in
liver, heart, skeletal muscle, kidney, brain, pancreas, and lung
tissue as well as in white and red blood cells (Giboney, 2005).
Human ALT, however, exists as two isoforms with identical
enzyme capacity, ALT1 and ALT2, although the presence of ALT2
appears to be restricted to non-hepatic tissue, in particular heart
and skeletal muscles (Glinghammar et al., 2009). A recent study
has demonstrated that assessing the percentage contribution
of ALT1 and ALT2 activities to total ALT activity in plasma
may distinguish hepatic from extrahepatic injury (Rafter et al.,
2012). The standard ALT activity assay currently used in clinical
practice, however, does not discriminate between serum ALT
from different organs or isoforms
Disease Phenotype
Drug-induced liver injury is generally classified into three
patterns of liver injury (hepatocellular, cholestatic, and mixed),
based originally on histological features. Hepatocellular type of
injury is characterized by hepatocyte necrosis and inflammation,
while bile stasis, portal inflammation and bile duct injury are
commonly found in cholestatic injury. Mixed injury is, as the
name suggests, a combination of these two liver injury types. As
biopsies not normally form part of the DILI diagnostic process,
the pattern of injury is mainly deduced based on liver profile
analytical values. More precisely, the relationship between ALT
and ALP values at DILI onset are used to determine the type
of liver injury according to the R formula, R = (ALT/upper
limit of normal, ULN) ÷ (ALP/ULN; Benichou, 1990; Aithal
et al., 2011). An R value ≥ 5 is indicative of hepatocellular
damage, R≤ 2 cholestatic damage and 2 < R < 5 mixed damage.
A recent comparison of ALT and AST elevations in a large DILI
cohort found that AST can reliably substitute for ALT in R value
calculations in cases were ALT values are absent at DILI onset,
but that gamma-glutamyl transpeptidase (GGT) is less reliable as
an ALP substitute (Robles-Diaz et al., 2015).
Clinical Course and Prognosis
An ALT value alone offers little predictive value with regards
to the clinical course of DILI, but can provide a prognostic
indication when combined with TBL. This is today referred to
as Hy’s Law and is based on clinical observations made by the
late Hyman Zimmerman that DILI patients with hepatocellular
type of liver injury and jaundice have a 10–50% higher risk of
mortality or need for liver transplantation. Hy’s Law has since
been defined more specifically as AST or ALT > 3 xULN and
TBL > 2 xULN in the absence of ALP elevations and alternative
reasons for ALT and TBL elevations, and is endorsed by the
American Food and Drug Administration as criteria for severe
DILI1.
The validity of Hy’s Law has now been confirmed in various
large DILI cohorts (Andrade et al., 2005; Björnsson and Olsson,
2005; Chalasani et al., 2015). However, the effect of ALP
increases on Hy’s Law have been questioned and recent findings
demonstrate that an ALP level greater than 2 xULN does not have
a protective role in acute liver failure development (Robles-Diaz
et al., 2014). While having relatively high sensitivity, Hy’s Law
lacks specificity as the majority of DILI cases meeting the Hy’s
Law criteria in fact have a favorable outcome with full recovery.
Using an extended range of analytical values we have developed
a composite algorithm with higher specificity for the prediction
of acute liver failure based on DILI onset data (Robles-Diaz et al.,
2014).
1http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf
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TABLE 1 | New serum/plasma DILI biomarker candidates.
Biomarker Study cohort (N) Comparison to alanine aminotransferase (ALT) Reference
GLDH Human: APAP overdose (33), cirrhosis and
liver injury (108), hepatic carcinoma (40)
Overall correlation coefficient: 0.88. Lower correlation in
APAP overdose than other liver injuries
Schomaker et al., 2013
GLDH Human: APAP overdose (129) Correlation coefficient (peak ALT): 0.45 Antoine et al., 2013
GLDH Human: healthy volunteers receiving
heparin
Correlation coefficient (peak ALT): 0.76 Harrill et al., 2012
MDH Human: APAP overdose (33), cirrhosis and
liver injury (108), hepatic carcinoma (40)
Overall correlation coefficient: 0.74. Less liver-specific
than ALT.
Schomaker et al., 2013
HMGB1 Mouse: APAP overdose Detectable elevations prior to ALT elevations. Peak
value reached faster than ALT.
Antoine et al., 2009
HMGB1 Human: APAP overdose (84) Correlation coefficient: 0.60. Acetylated HMGB1
associated with worse prognosis
Antoine et al., 2012
HMGB1 Human: APAP overdose (129) Correlation coefficient (peak ALT): 0.67. Can predict
clinical hepatotoxicity after APAP overdose prior to ALT.
Antoine et al., 2013
K18 Mouse: APAP overdose Detectable elevations of FL-K18 and cK18 prior to ALT. Antoine et al., 2009
K18 Human: APAP overdose (84) Correlation coefficient: 0.58. Full length K18 associated
with worse prognosis
Antoine et al., 2012
K18 Human: APAP overdose (129) Correlation coefficient (peak ALT): FL-K18, 0.59; cK18,
0.57. FL-K18 can predict clinical hepatotoxicity after
APAP overdose prior to ALT.
Antoine et al., 2013
K18 Humans: healthy volunteers receiving APAP
(58), participating in an extreme adventure
race (12)
Correlation coefficient (peak ALT): FL-K18, 0.70; cK18,
0.66. No elevation after muscular injury, which
increased ALT
Thulin et al., 2014
miR-122, mir-192 Mouse: APAP overdose Liver enriched miRs. Dose- and exposure
duration-dependent changes in plasma detectable
earlier than ALT.
Wang et al., 2014
miR-122, miR-192 Humans: APAP overdose (53) Increased serum level after APAP overdose. miR-122
correlation coefficient (peak ALT): 0.46.
Starkey Lewis et al., 2011
miR-122 Humans: healthy volunteers receiving APAP
(58), participating in an extreme adventure
race (12)
Correlation coefficient (peak ALT): 0.62. No elevation
after muscular injury, which increased ALT
Thulin et al., 2014
Eleven miRNAs profile Humans: APAP overdose and ischemic
hepatitis (49)
Diagnostic potential (elevated in APAP overdose but not
in ischemic patients). Lack of miRNA profile recovery
indicative of adverse patient outcome.
Ward et al., 2014
GLDH, glutamate dehydrogenase; MDH, malate dehydrogenase; HMGB1, high-mobility group box-1 protein; K18, keratin-18; FL-K18, full length K18; cK18, caspase-
cleaved fragment of K18; miR, microRNA.
NEW POTENTIAL BIOMARKERS IN DILI
The heightened interest in developing new more sensitive and
specific DILI biomarkers for early prediction and diagnosis2,3,4
has resulted in the discovery of several promising candidates
(Table 1). Many of these biomarker candidates were initially
identified using APAP models, but could also be promising for
aspects of idiosyncratic DILI.
Mechanistic-Based
Glutamate dehydrogenase (GLDH) is a mitochondrial enzyme
found primarily in the liver and to a lesser degree in
kidneys and trace amounts in skeletal muscles. This enzyme
is more tissue-specific than ALT and AST. Healthy individuals
present a stable and measurable level of serum GLDH that is
unaffected by age and gender (Schomaker et al., 2013). A rise




subsequent loss of mitochondrial membrane integrity, which
occurs during hepatocellular necrosis. GLDH correlates well
with ALT elevations in patients with various forms of clinically
demonstrated liver injury, including APAP overdose, but is not
sensitive enough to predict APAP hepatotoxicity prior to ALT
(Antoine et al., 2013; Schomaker et al., 2013). Furthermore,
healthy volunteers receiving subcutaneous heparin injection
have been reported to develop serum GLDH elevations in
conjunction with asymptomatic ALT elevations, which underline
the correlation between GLDH and ALT (Harrill et al., 2012).
Similar results have been found for malate dehydrogenase
(MDH), a constitutive enzyme in the citric acid cycle that is
released into the serum after tissue damage (Schomaker et al.,
2013). However, MDH is less tissue-specific and its serum level
is subsequently affected by extrahepatic tissue damage.
High-mobility group box 1 (HMGB1) is a chromatin-binding
protein with proinflammatory activity mediated through Toll-
like receptor and receptor for advanced glycation endproducts
signaling (Kubes and Mehal, 2012). It is passively released by
necrotic cells in a hypoacetylated form, but not by apoptotic
or secondary necrotic cells (Scaffidi et al., 2002). In contrast,
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it is actively secreted in a hyperacetylated form by immune
cells (Bonaldi et al., 2003). Hence, HMGB1 is reflective of cell
necrosis or activated immune cells depending on its acetylation
status. Keratin-18 (K18) is a member of the keratin protein
family, which is involved in cell structure and integrity. Similar
to HMGB1, full-length K18 is released passively during cell
necrosis. However, K18 undergoes caspase-mediated cleavage
as part of structural rearrangements during apoptosis and can
then be released into the blood stream (Ku et al., 2007). Hence,
differentiating serum concentrations of full-length and caspase-
cleaved K18 can provide an indication of the level of cell necrosis
and apoptosis occurring in a subject. The molecular forms of
HMGB1 and K18 have now been verified as sensitive blood-
based markers of acute liver injury and provide insight into
the mechanistic process of APAP hepatotoxicity (Antoine et al.,
2009, 2012). These biomarkers have also been found to be more
sensitive than ALT, with apparent elevations prior to ALT in
patients at first presentation after APAP overdose intake (Antoine
et al., 2013). The use of these biomarkers in clinical practice
could potentially improve the speed of clinical decision-making.
However, the value and clinical utility in cases with idiosyncratic
DILI is still unknown.
MicroRNA
MicroRNAs (miRNAs) are small (20–24 nucleotides) non-
coding RNAs involved in post-transcriptional regulation of
gene expression. Organ damage usually results in miRNAs
being released into the bloodstream and to some degree also
in urine. MiRNAs are relatively stable in biofluids, a feature
that has contributed to that circulating miRNAs have received
much attention lately as potential non-invasive DILI biomarker
candidates. To date several studies have reported changes in
serum miRNA concentrations during liver injury (Zhang et al.,
2010; Starkey Lewis et al., 2011; Ward et al., 2014). MiR-122
and miR-192 were the first circulating miRNAs demonstrated
to increase after toxic APAP doses in mice and soon after were
confirmed to behave in a similar manner in human subjects
(Wang et al., 2009; Starkey Lewis et al., 2011). MiR-122 and
miR-192 are both liver-enriched miRNAs, with miR-122 variants
accounting for approximately 72% of the total liver miRNA
population in mice (Lagos-Quintana et al., 2002). Serum miR-
122 is detectable at an early stage of hepatocellular damage as
demonstrated in hospital admitted patients shortly after APAP
overdose intake when ALT still remained normal (Antoine et al.,
2013). This feature makes miR-122 particularly interesting for
use during early phase human trials to detect drug candidates
with hepatotoxicity potential, which may go undetected with the
current biomarkers. Furthermore, miR-122 is more liver-specific
than ALT as demonstrated in a human cohort with exercise-
induced muscular injury, in which miR-122 remained stable
while increases in ALT were detected (Thulin et al., 2014).
Emerging data also indicate that miRNA-122 could have a
prognostic value, with higher early serum levels reported in APAP
overdose patients who met the King’s College Criteria for liver
transplantation (Starkey Lewis et al., 2011). However, the value
of miR-122 for idiosyncratic DILI remains to be determined. It
is interesting to note that while miR-122 shows much promise as
a sensitive early blood borne DILI biomarker, urine levels of this
miRNA does not increase notably after APAP overdoses neither
in rats nor in humans (Yang et al., 2012, 2015). Recent data
also suggest that serum miRNA profiles, rather than individual
miRNAs, could have a higher diagnostic value. This is supported
by a comparison of an 11-miRNA panel in acute liver injury
patients of different etiologies (Ward et al., 2014).
Exosomes
While miRNAs can enter the blood stream passively during
cell necrotic and/or apoptotic cell death, active release also
occurs in a regulated manner via exosomes. Exosomes are one
of several forms of membrane-surrounded structures released
by almost all types of cells. The complete role of exosomes
besides transportation and delivery of various substances,
such as signaling molecules and cellular waste, is yet to be
elucidated (Yang et al., 2014). The constituents of exosomes
are not limited to miRNAs but also include proteins, lipids,
and additional nucleic acids (mRNAs). Exosomes have received
much attention lately as a potential source for DILI biomarker
explorations, seeing that exosome constituents change under
cellular stress conditions (Wetmore et al., 2010; de Jong et al.,
2012). Circulating exosomes originating from various tissues
are found in many types of body fluids, with blood and
urine being the more interesting sources for non-invasive
biomarkers. A major challenge is subsequently to determine
hepatocyte-derived exosomes. Nevertheless, promising results
have emerged using animal models to demonstrate increases
in exosomal liver-specific mRNAs (e.g., albumin, fibrinogen
B β-polypeptide, haptoglobin, and β-actin) and liver-enriched
miRNAs (miR-122 and miR-155) during acute liver injury
(Wetmore et al., 2010; Bala et al., 2012). Interestingly, while
increased levels of miR-122 and miR-155 were detected
in circulating exosome-rich serum/plasma fractions in mice
with alcohol- or lipopolysaccharide-induced liver injury, these
miRNAs were found to be elevated in protein-rich serum/plasma
fractions in mice with APAP hepatotoxicity, suggesting that
miRNA compartment distribution pattern could also differ
depending on the etiology (Bala et al., 2012). Variations in
exosome-derived miRNA expression profiles have also been
reported for additional liver conditions, such as chronic viral
hepatitis B and C and non-alcoholic steatohepatitis compared
to healthy controls. Furthermore, the miRNA expression pattern
was found to reflect fibrosis stage and grade of liver inflammation
in patients with chronic viral hepatitis C (Murakami et al., 2012).
“Omics” Derived Biomarkers
The introduction of omics technologies offers a new approach
for biomarker exploration studies. The ability to screen a
large number of molecules (metabolites, proteins, DNA, etc.)
simultaneously enables the identification of ‘toxicity signatures’,
which could be used to enhance preclinical safety assessments
and disease diagnostics. Omics-based studies can also provide
information on the underlying mechanisms of distinct forms
of DILI that could further facilitate the identification of
early diagnostic biomarkers. Metabolomics is recognized as a
promising technique, typically through mass spectrometry or
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nuclear magnetic resonance spectroscopy. This technique enables
the evaluation of global metabolic changes and subsequently the
identification of specific metabolic profiles associated with for
example diseases or treatment responses. Metabolomics has been
successfully applied to identify potential biomarker candidates in
many types of liver diseases, including non-alcoholic fatty liver
disease, steatosis, fibrosis, cirrhosis, hepatocellular carcinoma,
and cholangiocarcinoma (reviewed by Beyog˘lu and Idle, 2013).
Furthermore, a comparison of plasma metabolic profiles of
patients diagnosed with autoimmune hepatitis, primary biliary
cirrhosis, autoimmune hepatitis/primary biliary cirrhosis overlap
syndrome, DILI and healthy controls resulted in a metabolic
autoimmune hepatitis phenotype with >93% sensitivity and
specificity (Wang et al., 2014). Similarly, serum γ-glutamyl
dipeptide levels have been demonstrated as potential biomarkers
capable of discriminating between different forms of hepatic
diseases (Soga et al., 2011).
However, in the field of hepatotoxicity, metabolomics
studies performed to date are mainly limited to intrinsic
DILI in animal or in vitro models. An ultra-performance
liquid chromatography/time-of-flight tandem mass spectrometry
analysis of galactosamine-treated rat sera found differences in
several metabolites such as glucose, amino acids, and membrane
lipids compared with control rats, with some of these correlating
with the degree of histologically determined liver damage
(Gonzalez et al., 2012). A similar study of sera from drug-treated
rats found increases in bile acid levels in addition to several
other metabolite differences, which combined with conventional
clinical chemistry markers may improve the robustness and
accuracy of a hepatotoxicity diagnosis (Buness et al., 2014).
Recent animal studies also support that metabolic profiles,
rather than individual metabolites, can predict hepatotoxicity,
including idiosyncratic hepatotoxicity (Sun et al., 2014; Li et al.,
2016). Metabolic profiling in urine has also been performed in
search for metabolites associated with DILI. Healthy volunteers
administered non-toxic levels of APAP presented both urine
and plasma metabolic alterations when comparing pre- and
post-dosing samples, which were more sensitive than changes
in serum biochemical parameter over the study period (Kim
et al., 2013). It should be pointed out that while many metabolic
studies to date coincide in detecting variations in endogenous
metabolites, the identified metabolites often vary between studies.
Differences in study design as well as treatments could lead
to such variations. It is also important to keep in mind that
interindividual differences are common in metabolomics due
to this method being very sensitive and subsequently can
reflect variations in environmental and host conditions between
subjects. Nevertheless, metabolomics could be a practical method
for identifying DILI patients shortly after starting a new
drug treatment and subsequently minimize serious liver injury
through early treatment discontinuation when specific metabolic
changes are detected. In addition to metabolomics, proteomics
can be useful in the search for more specific DILI biomarkers.
An exploratory comparison of global serum proteomes in DILI
has reported promising results with apolipoprotein E expression
demonstrating the greatest power to differentiate DILI from
controls (Bell et al., 2012), while cadherin 5 and fatty acid binding
protein 1 were found to be associated with DILI using an antibody
bead array approach (Mikus et al., 2016). Likewise, genome-wide
association studies of DILI cohorts have provided a number of
specific HLA alleles that appear to be associated with distinct
forms of DILI. These alleles, which have high negative predictive
values, may be used as biomarkers to rule out DILI or identify
the correct causative agent in patients taking more than one
hepatotoxic agent, and subsequently facilitate the DILI diagnostic
process (Aithal, 2015). However, the DILI forms associated with
HLA risk alleles to date are limited to more common causative
agents and many forms of DILI consequently lack determined
HLA associations.
FUTURE PERSPECTIVES
Alanine aminotransferase, aspartate aminotransferase, alkaline
phosphatase, and total bilirubin are currently the only approved
DILI biomarkers in clinical practice. While fulfilling an important
role in disease diagnostics, these biomarkers are not specific for
hepatotoxicity, as an increase in any of these biochemical values
is detected during practically all liver conditions. Furthermore,
these biomarkers lack sensitivity as they appear once liver
damage has developed and are consequently of limited use
for predicting potential liver injury at a very early stage.
This is of particular importance in clinical trials during
drug development. The presence of DILI biomarkers with
enhanced specificity and sensitivity may detect drug candidates
with hepatotoxicity potential earlier in the drug development
process and subsequently reduce the number of late stage drug
attrition and postmarketing drug withdrawals. Furthermore,
such biomarker would improve patient safety, due to offering
improved monitoring during drug treatment initiation, as well as
a faster and more accurate DILI diagnosis.
The lack of specific DILI biomarkers is to a large extent a
consequence of the limited mechanistic understanding of this
condition. The arrival of the “omics era” has brought hope
and anticipation of scientific breakthroughs on the mechanistic
side of DILI. Substantial progress has been made recently
with the identification of new mechanistic-based biomarker
candidates, such as HMGB1, K18, and miR-122. However, further
efforts to explore and refine new improved DILI biomarker
panels are needed. To be valid in clinical practice such non-
invasive biomarkers not only need to demonstrate substantial
specificity and sensitivity, but also need to be reasonably stable
in extracted body fluids to allow reliable detection, as well as
being easily assayed. The ability to validate new DILI biomarker
candidates is restricted due to the current lack of fully functional
animal models for idiosyncratic DILI. Although improved cell
culture system such as induced pluripotent stem cell-derived
hepatocytes are emerging, large DILI patient cohorts are the
foremost approach for biomarker validations. This highlights the
importance of collaborative efforts to establish DILI registries,
which can circumvent the low DILI incidence rate generally
encountered in individual hospital units. The Pro-Euro-DILI
Registry is a recently established international DILI registry
with serial biological sample collections from DILI onset to
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normalization of enrolled patients, intended for future DILI
biomarker studies and validations (Slim et al., 2016).
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